Suppr超能文献

相似文献

1
Bone marrow microenvironment in multiple myeloma progression.
J Biomed Biotechnol. 2012;2012:157496. doi: 10.1155/2012/157496. Epub 2012 Oct 3.
2
The impact of the bone marrow microenvironment on multiple myeloma (Review).
Oncol Rep. 2019 Oct;42(4):1272-1282. doi: 10.3892/or.2019.7261. Epub 2019 Aug 5.
3
Targeting the bone marrow microenvironment in multiple myeloma.
Immunol Rev. 2015 Jan;263(1):160-72. doi: 10.1111/imr.12233.
5
Multiple myeloma bone marrow niche.
Curr Pharm Biotechnol. 2009 Apr;10(3):345-6. doi: 10.2174/138920109787847493.
6
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Biomolecules. 2023 Nov 7;13(11):1629. doi: 10.3390/biom13111629.
7
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e752-e768. doi: 10.1016/j.clml.2020.05.026. Epub 2020 Jun 7.
9
The role of the bone marrow microenvironment in multiple myeloma.
Histol Histopathol. 2005 Oct;20(4):1227-50. doi: 10.14670/HH-20.1227.
10
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Cancer Res. 2020 Mar 1;80(5):1036-1048. doi: 10.1158/0008-5472.CAN-19-0284. Epub 2020 Jan 7.

引用本文的文献

1
Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.
Medicine (Baltimore). 2025 Sep 5;104(36):e44276. doi: 10.1097/MD.0000000000044276.
2
Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers.
Front Pharmacol. 2025 Jun 17;16:1589090. doi: 10.3389/fphar.2025.1589090. eCollection 2025.
3
Lipid metabolism in multiple myeloma: pathogenesis, therapeutic opportunities, and future directions.
Front Oncol. 2025 Mar 5;15:1531928. doi: 10.3389/fonc.2025.1531928. eCollection 2025.
6
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.
Pharmgenomics Pers Med. 2024 Dec 21;17:573-609. doi: 10.2147/PGPM.S350238. eCollection 2024.
8
Updates on CAR T cell therapy in multiple myeloma.
Biomark Res. 2024 Sep 12;12(1):102. doi: 10.1186/s40364-024-00634-5.
10
Role of Immune Cells and Immunotherapy in Multiple Myeloma.
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461.

本文引用的文献

2
Myeloma as a model for the process of metastasis: implications for therapy.
Blood. 2012 Jul 5;120(1):20-30. doi: 10.1182/blood-2012-01-379024. Epub 2012 Apr 24.
3
Angiogenesis and multiple myeloma.
Cancer Microenviron. 2011 Dec;4(3):325-37. doi: 10.1007/s12307-011-0072-9. Epub 2011 Jul 7.
5
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
Blood. 2011 Apr 7;117(14):3720-32. doi: 10.1182/blood-2010-07-273417. Epub 2011 Feb 8.
7
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
Blood. 2010 Mar 25;115(12):2430-40. doi: 10.1182/blood-2009-07-232801. Epub 2010 Jan 19.
8
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.
Clin Cancer Res. 2009 Sep 1;15(17):5369-78. doi: 10.1158/1078-0432.CCR-09-0040. Epub 2009 Aug 18.
9
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood. 2009 Jul 9;114(2):371-9. doi: 10.1182/blood-2008-11-191577. Epub 2009 May 5.
10
The metastatic niche: adapting the foreign soil.
Nat Rev Cancer. 2009 Apr;9(4):285-93. doi: 10.1038/nrc2621.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验